MX2014015631A - Composiciones farmaceuticas y tratamiento de mastitis. - Google Patents

Composiciones farmaceuticas y tratamiento de mastitis.

Info

Publication number
MX2014015631A
MX2014015631A MX2014015631A MX2014015631A MX2014015631A MX 2014015631 A MX2014015631 A MX 2014015631A MX 2014015631 A MX2014015631 A MX 2014015631A MX 2014015631 A MX2014015631 A MX 2014015631A MX 2014015631 A MX2014015631 A MX 2014015631A
Authority
MX
Mexico
Prior art keywords
mastitis
treatment
pharmaceutical compositions
pharmaceutical composition
relates
Prior art date
Application number
MX2014015631A
Other languages
English (en)
Other versions
MX368153B (es
Inventor
Robrecht Froyman
Heinz-Georg Wetzstein
Kristine Fraatz
Wiehl Wolfgang
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48672650&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014015631(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of MX2014015631A publication Critical patent/MX2014015631A/es
Publication of MX368153B publication Critical patent/MX368153B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a una composición farmacéutica y a procedimientos de tratamiento y/o prevención de mastitis en mamíferos no humanos. Más en particular, la presente invención se refiere al tratamiento de mastitis en vacas. La composición farmacéutica comprende una mezcla de un ácido fosfónico y al menos un agente antimicrobiano.
MX2014015631A 2012-06-29 2013-06-25 Composiciones farmacéuticas y tratamiento de mastitis. MX368153B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666312P 2012-06-29 2012-06-29
PCT/EP2013/063310 WO2014001353A1 (en) 2012-06-29 2013-06-25 Pharmaceutical compositions and treatment of mastitis

Publications (2)

Publication Number Publication Date
MX2014015631A true MX2014015631A (es) 2015-04-09
MX368153B MX368153B (es) 2019-09-20

Family

ID=48672650

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015631A MX368153B (es) 2012-06-29 2013-06-25 Composiciones farmacéuticas y tratamiento de mastitis.

Country Status (22)

Country Link
US (1) US10265330B2 (es)
EP (1) EP2866812B1 (es)
JP (1) JP6246804B2 (es)
KR (1) KR20150030707A (es)
CN (2) CN104379151A (es)
AR (1) AR091603A1 (es)
AU (1) AU2013283375B2 (es)
BR (1) BR112014031866A2 (es)
CA (1) CA2877794C (es)
CL (1) CL2014003503A1 (es)
CO (1) CO7240376A2 (es)
CR (1) CR20140594A (es)
DO (1) DOP2014000300A (es)
EC (1) ECSP14033371A (es)
HK (1) HK1206623A1 (es)
IL (1) IL235768A0 (es)
MX (1) MX368153B (es)
NZ (1) NZ702087A (es)
PE (1) PE20150199A1 (es)
PH (1) PH12014502864A1 (es)
RU (1) RU2659430C2 (es)
WO (1) WO2014001353A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8757092B2 (en) 2011-03-22 2014-06-24 Eco-Composites Llc Animal bedding and associated method for preparing the same
US9737047B2 (en) 2011-03-22 2017-08-22 Ccd Holdings Llc Method for the treatment, control, minimization, and prevention of bovine mastitis
PE20150199A1 (es) 2012-06-29 2015-01-31 Bayer Animal Health Gmbh Composiciones farmaceuticas y tratamiento de mastitis
CN105492005A (zh) * 2013-02-08 2016-04-13 罗达制药有限公司 治疗包括***炎的微生物感染的方法
EA030750B1 (ru) 2013-03-15 2018-09-28 Мериал, Инк. Противомикробная полиамидная композиция и способ лечения мастита
EP3046605B1 (en) 2013-09-16 2019-01-09 Zoetis Services LLC Assembly for sequentially delivering substances, and associated methods
JP2016088918A (ja) * 2014-11-11 2016-05-23 大山乳業農業協同組合 ***炎治療・予防用組成物、並びに、***炎の治療・予防方法
DK3124016T3 (da) * 2015-07-31 2019-12-09 Univ Warszawski Medyczny Antipsoriatisk emulsionspræparat omfattende cefazolin
WO2018022451A1 (en) * 2016-07-27 2018-02-01 The Trustees Of The University Of Pennsylvania Drug target for treating veterinary infections and methods of using same
JPWO2021006317A1 (es) * 2019-07-11 2021-01-14
CA3205453A1 (en) * 2020-12-24 2022-06-30 Intervet International B.V. Methods of treating mastitis with an orthosomycin antimicrobial compound
RU2762088C1 (ru) * 2021-05-05 2021-12-15 Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский ветеринарный институт патологии, фармакологии и терапии" (ФГБНУ "ВНИВИПФиТ") Способ лечения мастита у коров
CN113368043A (zh) * 2021-06-11 2021-09-10 吉林大学 一种复方阿莫西林***注入剂及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034099A (en) * 1974-03-29 1977-07-05 The Upjohn Company Compositions and method for treating mastitis in milk animals
US4210635A (en) 1978-02-15 1980-07-01 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
US4330529A (en) * 1978-02-15 1982-05-18 Fujisawa Pharmaceutical Co., Ltd. Antibacterial composition
JPS62129217A (ja) * 1985-12-02 1987-06-11 Fujisawa Pharmaceut Co Ltd 医薬用殺菌組成物
DE69816304D1 (de) * 1997-07-29 2003-08-14 Kaneka Corp Verwendung eines rifamycinderivates zur behandlung von mastitis bei tieren
CA2529405A1 (en) * 2003-07-31 2005-02-03 Pharmacia & Upjohn Company Llc Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
DE102004054873A1 (de) * 2004-11-12 2006-05-18 Bayer Healthcare Ag Behandlung von Mastitis
EP2018864A1 (en) 2007-07-23 2009-01-28 Biomet Deutschland GmbH Pharmaceutical composition, substrate comprising a pharmaceutical composition, and use of a pharmaceutical composition
CN101744827B (zh) 2008-12-15 2012-05-30 天津中敖生物科技有限公司 治疗鸡大肠杆菌的药物组合物及其制备方法、应用
US8449916B1 (en) * 2009-11-06 2013-05-28 Iowa State University Research Foundation, Inc. Antimicrobial compositions and methods
EP2404601A1 (en) 2010-07-06 2012-01-11 BioAgency AG New drug combinations for the treatment of Malaria
CN101879172B (zh) 2010-07-13 2012-07-18 杨建彬 头孢噻呋钠复方制剂
EA021846B1 (ru) 2011-05-11 2015-09-30 ЛИМОНОВ, Виктор Львович Фармацевтическая композиция антибактериального действия для парентерального применения, способ ее получения
PE20150199A1 (es) 2012-06-29 2015-01-31 Bayer Animal Health Gmbh Composiciones farmaceuticas y tratamiento de mastitis

Also Published As

Publication number Publication date
PE20150199A1 (es) 2015-01-31
CN104379151A (zh) 2015-02-25
BR112014031866A2 (pt) 2022-02-01
CO7240376A2 (es) 2015-04-17
KR20150030707A (ko) 2015-03-20
DOP2014000300A (es) 2015-07-15
CA2877794C (en) 2020-08-04
RU2015102562A (ru) 2016-08-20
EP2866812B1 (en) 2017-10-04
CN110522914A (zh) 2019-12-03
EP2866812A1 (en) 2015-05-06
RU2659430C2 (ru) 2018-07-02
CA2877794A1 (en) 2014-01-03
AU2013283375B2 (en) 2018-04-26
US10265330B2 (en) 2019-04-23
JP6246804B2 (ja) 2017-12-13
MX368153B (es) 2019-09-20
ECSP14033371A (es) 2015-09-30
AU2013283375A1 (en) 2014-12-18
CR20140594A (es) 2015-02-06
CL2014003503A1 (es) 2015-05-04
WO2014001353A1 (en) 2014-01-03
HK1206623A1 (en) 2016-01-15
PH12014502864A1 (en) 2015-02-23
AR091603A1 (es) 2015-02-18
IL235768A0 (en) 2015-01-29
US20150164926A1 (en) 2015-06-18
JP2015521644A (ja) 2015-07-30
NZ702087A (en) 2016-12-23

Similar Documents

Publication Publication Date Title
PH12014502864A1 (en) Pharmaceutical compositions and treatment of mastitis
EP3269378A4 (en) Composition for preventing or treating inflammatory diseases, comprising lactic acid bacteria-derived extracellular vesicles as active ingredients
NZ712876A (en) Antimicrobial polyamide compositions and mastitis treatment
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MY185139A (en) Substituted imidazopyridazines
PH12016501807A1 (en) Novel compounds
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
TN2015000371A1 (en) Substituted imidazopyridazines
PH12017501133A1 (en) Pyrazolopyridinamines
MX2013013649A (es) Compuestos de quinona para tratar enfermedades mediadas por ape1.
PH12016501814A1 (en) Inhibitors of the wnt signalling pathways
IN2014DN07326A (es)
PH12014502065A1 (en) Vesicular formulations
EP2579863A4 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).
WO2014031982A3 (en) Methods and compositions for treating pain
MA39762A (fr) Nouveaux composés
MX2016013108A (es) Nueva composicion para el tratamiento de la tricomoniasis.
TN2014000091A1 (en) Amino-substituted imidazopyridazines
TN2010000463A1 (en) Compositions and methods for preparing and using same
UA105703C2 (uk) 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти
WO2012122030A3 (en) Oral bacteria and uses thereof

Legal Events

Date Code Title Description
FG Grant or registration